Eczema-to-asthma link runs through basophils, researchers say

Suppressing basophils in a mouse model of atopic dermatitis can prevent later allergic airway inflammation, according to a new study from a team at Friedrich-Alexander-Universität Erlangen-Nürnberg.
Basophils have long been viewed as modest effector cells in IgE-mediated responses. A growing body of work now casts them as orchestrators of type 2 immunity. This review in Frontiers in Immunology argues basophils are the connective tissue of the atopic march—from atopic eczema in infancy to allergic asthma and food allergies.
"Atopic eczema disrupts the skin barrier, enabling substances from the environment to enter the body more easily," said Prof. Dr. David Vöhringer in a press release. He is Director of the Department of Infection Biology at Universitätsklinikum Erlangen, and an author of the paper.
In the study, the researchers applied an allergen to the skin of mice with atopic dermatitis symptoms and simultaneously suppressed the formation of basophils for a short period. When the allergen was later inhaled, the lungs showed only a weak inflammatory response, whereas control animals responded markedly—similar to a severe asthma attack. "This shows that basophils in the skin cause the lung to become hypersensitive to the allergen as well," said co-author Dr. Daniel Radtke. "We do not yet know how this happens."
Interleukin-4, released abundantly by activated basophils, may amplify the response, with components of it reaching the airways via the bloodstream and priming bronchial epithelium. The review also cataloged basophil modulation of dendritic cells, ILC2s, and Th2 differentiation, and their promotion of goblet-cell hyperplasia and mucus production in allergic lung disease.
The clinical implication is preventive. "It is very important to treat allergic skin reactions quickly and effectively in early childhood," Prof. Vöhringer said, as prolonged basophil activation could significantly increase asthma risk. Agents that reduce basophil IL-4 production are already in development for eczema. "Perhaps it may also be possible to reduce the risk of patients developing asthma later in life with these agents," he added. "Whether that is the case remains to be seen."



Comments